MedPath

TENGION

🇺🇸United States
Ownership
-
Established
2003-01-01
Employees
-
Market Cap
-
Website
http://www.tengion.com/

Clinical Trials

8

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:3
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (50.0%)
Phase 2
3 (50.0%)

A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes

Phase 1
Terminated
Conditions
Chronic Kidney Disease
First Posted Date
2013-12-11
Last Posted Date
2014-12-11
Lead Sponsor
Tengion
Target Recruit Count
1
Registration Number
NCT02008851
Locations
🇺🇸

University of Chicago Medicine, Chicago, Illinois, United States

🇺🇸

LSU Health Care Services, New Orleans, Louisiana, United States

🇺🇸

Brigham & Women's Hospital, Boston, Massachusetts, United States

and more 2 locations

Study of an Autologous Neo-Kidney Augment in Patients With Chronic Kidney Disease

Phase 1
Terminated
Conditions
Chronic Kidney Disease
First Posted Date
2013-05-03
Last Posted Date
2014-12-11
Lead Sponsor
Tengion
Target Recruit Count
6
Registration Number
NCT01846715
Locations
🇸🇪

Karolinska Institute, Stockholm, Sweden

🇸🇪

Uppsala University Hospital, Uppsala, Sweden

Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit

Phase 1
Completed
Conditions
Bladder Cancer
First Posted Date
2010-03-16
Last Posted Date
2014-12-10
Lead Sponsor
Tengion
Target Recruit Count
8
Registration Number
NCT01087697
Locations
🇺🇸

The University of Chicago, Chicago, Illinois, United States

🇺🇸

The Johns Hopkins Medical Institutions, Baltimore, Maryland, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 3 locations

Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure

Completed
Conditions
Bladder Disease
First Posted Date
2008-02-14
Last Posted Date
2010-12-22
Lead Sponsor
Tengion
Target Recruit Count
6
Registration Number
NCT00615043
Locations
🇺🇸

University of Alabama, Birmingham, Birmingham, Alabama, United States

Autologous Neo-Bladder Construct in Non-Neurogenic Overactive Bladder and Urge Predominant Incontinence

Phase 2
Withdrawn
Conditions
Overactive Bladder
First Posted Date
2008-01-15
Last Posted Date
2018-06-08
Lead Sponsor
Tengion
Registration Number
NCT00594139
Locations
🇺🇸

Vanderbilt University, Nashville, Tennessee, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.